相关实验视频

Updated: Jan 6, 2026

Intravital Microscopy of Monocyte Homing and Tumor-Related Angiogenesis in a Murine Model of Peripheral Arterial Disease

Intravital Microscopy of Monocyte Homing and Tumor-Related Angiogenesis in a Murine Model of Peripheral Arterial Disease

Published on: August 26, 2017

抑制单细胞迁移可以减少动脉血栓形成,并促进血栓溶解

Hee Jeong Jang^1,2, Jiwon Kim^1,2, Ha Kim^1,2

¹Department of Neurology (H.J.J., J.K., H.K., T.K., D.-E.K.), Dongguk University Ilsan Hospital, Goyang, Republic of Korea.

|October 10, 2025

概括

在动脉血栓形成模型中,CCR2淘汰会减少血小板聚合和血栓形成. 这种单细胞缺乏导致较小,较多孔,易于溶解的血块,影响中风和心肌梗塞研究.

科学领域:

心血管生物学心血管生物学
血液学血液学血液学
免疫学免疫学免疫学

背景情况:

单细胞是静脉血栓形成的关键,但它们在动脉血栓形成 (中风,心肌梗塞) 中的作用尚不清楚.
了解单细胞参与动脉血栓形成对于开发新疗法至关重要.

研究的目的:

调查CC化学受体2 (CCR2) 和单细胞缺陷在动脉血栓形成中的作用.
确定CCR2淘汰对血小板功能,凝血,血栓特征和溶解的影响.

主要方法:

在CCR2淘汰赛 (CCR2-/-) 和野生型 (WT) 小鼠中使用FeCl3诱导的动脉血栓形成模型.
采用了静脉内显微镜,流细胞计,血小板功能检测和微型CT成像.
评估了血栓体积,多孔度,纤维素交叉链接和对血栓溶解的反应.

主要成果:

在CCR2-/-小鼠中,血小板聚合减少,单细胞-血小板聚合较少.
在CCR2-/-小鼠中的血栓较小,较多孔,纤维素交叉连接减少.
CCR2缺乏症增强了组织类型等离子体激活剂 (tPA) 介导的血栓溶解.

结论:

CCR2对抗作用会损害血小板功能,并降低XIII因子 (FXIII) 的水平.
单细胞缺乏促进了较小,更容易溶解的动脉瘤的形成.
准CCR2可能为动脉血栓形成提供治疗策略.

关键词:

克洛皮多格雷尔的使用方法纤维素纤维素是一种纤维素.一个单细胞单细胞.血小板聚合血小板聚合血栓形成的原因是血栓形成.

更多相关视频

Quantification of Monocyte Transmigration and Foam Cell Formation from Individuals with Chronic Inflammatory Conditions

Quantification of Monocyte Transmigration and Foam Cell Formation from Individuals with Chronic Inflammatory Conditions

Published on: October 17, 2017

Isolation and Intravenous Injection of Murine Bone Marrow Derived Monocytes

Isolation and Intravenous Injection of Murine Bone Marrow Derived Monocytes

Published on: December 27, 2014

相关概念视频

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...

Clot Retraction and Fibrinolysis

Clot Retraction and Fibrinolysis

After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.

Venous Thrombosis III: Interprofessional Care

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...

Atherosclerosis III: Management

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...